Adamis Pharmaceuticals Corporation
Hedge Funds Holdings
Last updated:
Adamis Pharmaceuticals Corporation‘s stocks are currently a part of 43 hedge funds’ portfolios, which represents 9.98% of the total amount of its stocks outstanding. This makes up a total of 12.92M shares of Adamis Pharmaceuticals Corporation. Compared to the previous quarter, the number fell by -8.87% or -1.25M shares fewer. As for the holding position changes, 16.28% (7) of current hedge fund investors increased the number of shares held, 30.23% (13) of current holders sold a part of the shares held, and 18.6% (8) closed the holdings completely. 3 hedge funds are new holders of Adamis Pharmaceuticals Corporation stock in Q1 2022, it is 6.98% of total holders.
Hedge funds holding Adamis Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 44 |
|---|---|
| Q3 2017 | 44 |
| Q4 2017 | 57 |
| Q1 2018 | 51 |
| Q2 2018 | 48 |
| Q3 2018 | 55 |
| Q4 2018 | 56 |
| Q1 2019 | 55 |
| Q2 2019 | 49 |
| Q3 2019 | 46 |
| Q4 2019 | 36 |
| Q1 2020 | 42 |
| Q2 2020 | 42 |
| Q3 2020 | 44 |
| Q4 2020 | 36 |
| Q1 2021 | 51 |
| Q2 2021 | 49 |
| Q3 2021 | 50 |
| Q4 2021 | 48 |
| Q1 2022 | 43 |
Hedge funds changes in Adamis Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 19 | 13 | 5 | 4 | 3 |
|---|---|---|---|---|---|
| Q3 2017 | 8 | 17 | 13 | 7 | -1 |
| Q4 2017 | 19 | 18 | 10 | 6 | 4 |
| Q1 2018 | 7 | 15 | 17 | 12 | 0 |
| Q2 2018 | 8 | 8 | 11 | 9 | 12 |
| Q3 2018 | 12 | 25 | 8 | 6 | 4 |
| Q4 2018 | 10 | 8 | 17 | 9 | 12 |
| Q1 2019 | 11 | 13 | 11 | 12 | 8 |
| Q2 2019 | 8 | 10 | 13 | 13 | 5 |
| Q3 2019 | 8 | 10 | 11 | 11 | 6 |
| Q4 2019 | 6 | 8 | 9 | 16 | -3 |
| Q1 2020 | 11 | 7 | 4 | 4 | 16 |
| Q2 2020 | 8 | 7 | 6 | 7 | 14 |
| Q3 2020 | 12 | 7 | 9 | 10 | 6 |
| Q4 2020 | 3 | 11 | 5 | 12 | 5 |
| Q1 2021 | 19 | 11 | 6 | 4 | 11 |
| Q2 2021 | 10 | 18 | 3 | 12 | 6 |
| Q3 2021 | 6 | 13 | 8 | 5 | 18 |
| Q4 2021 | 7 | 14 | 6 | 9 | 12 |
| Q1 2022 | 3 | 7 | 13 | 8 | 12 |
Hedge funds changes in Adamis Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 5,140,000 | 1,625,000 |
|---|---|---|
| Q3 2017 | 6,551,000 | 953,000 |
| Q4 2017 | 504,000 | 737,000 |
| Q1 2018 | 834,000 | 508,000 |
| Q2 2018 | 718,000 | 696,000 |
| Q3 2018 | 561,000 | 2,422,000 |
| Q4 2018 | 229,000 | 975,000 |
| Q1 2019 | 311,000 | 568,000 |
| Q2 2019 | 85,000 | 209,000 |
| Q3 2019 | 0 | 24,000 |
| Q4 2019 | 238,000 | 8,000 |
| Q1 2020 | 50,000 | 0 |
| Q2 2020 | 339,000 | 0 |
| Q3 2020 | 1,325,000 | 131,000 |
| Q4 2020 | 316,000 | 84,000 |
| Q1 2021 | 996,000 | 1,186,000 |
| Q2 2021 | 1,852,000 | 930,000 |
| Q3 2021 | 2,529,000 | 713,000 |
| Q4 2021 | 914,000 | 100,000 |
| Q1 2022 | 673,000 | 24,000 |